¼¼°èÀÇ CC ÄɸðÄ«ÀÎ ¼ö¿ëü 5Çü ½ÃÀå º¸°í¼­(2025³â)
CC Chemokine Receptor Type 5 Global Market Report 2025
»óǰÄÚµå : 1703087
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,244,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,026,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,807,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

CC ÄɸðÄ«ÀÎ ¼ö¿ëü 5Çü ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö 22¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGRÀº 10.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº HIV ¶Ç´Â AIDSÀÇ È®»ê, ÀÇ·á ÀÎÇÁ¶ó, °æÁ¦Àû Àμ¾Æ¼ºê, ÀÇ·á ¼ö¿ä Áõ°¡, °æÁ¦ ¼ºÀå¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¾Ï Ä¡·á °ü·Ã ¿¬±¸°³¹ß È®´ë, º´¿ë¿ä¹ý °³¹ß, ÀǾàǰ Á¦Á¶ °³¹ß, Àü·«Àû Á¦ÈÞ ¹× ÆÄÆ®³Ê½Ê, ÀÓ»ó½ÃÇè È®´ë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È CC ÄɸðÄ«ÀÎ ¼ö¿ëü 5Çü(CCR5) ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸¸¼ºÁúȯÀº ½ÉÀ庴, ´ç´¢º´, °üÀý¿°°ú °°Àº Àå±âÀûÀÎ ÁúȯÀ¸·Î ¼­¼­È÷ ÁøÇàµÇ¾î ÀϹÝÀûÀ¸·Î Áö¼ÓÀûÀÎ °ü¸®°¡ ÇÊ¿äÇÑ ÁúȯÀÔ´Ï´Ù. ¸¸¼ºÁúȯ Áõ°¡´Â Àα¸ °í·ÉÈ­, ½Ä½À°ü Àå¾Ö, ¿îµ¿ ºÎÁ·, ºñ¸¸ µî »ýȰ½À°ü °ü·Ã À§Çè¿äÀÎ Áõ°¡¿¡ ±âÀÎÇϸç, CCR5´Â Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV)¿Í °°Àº ¸¸¼ºÁúȯ¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ¸é¿ª¼¼Æ÷¿¡ ¹ÙÀÌ·¯½ºÀÇ Ä§ÀÔÀ» ÃËÁøÇϰí Áúº´ ÁøÇà¿¡ ±â¿©ÇÏ´Â ÇÙ½É ¼ö¿ëü ¿ªÇÒÀ» ÇÕ´Ï´Ù. Áúº´ ÁøÇà¿¡ ±â¿©ÇÏ´Â ÇÙ½É ¼ö¿ëü·Î ÀÛ¿ëÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 10¿ù ½ºÀ§½º¿¡ ±â¹ÝÀ» µÐ HIV ¿¹¹æ¿¡ ÃÊÁ¡À» ¸ÂÃá ¼¼°è ÀÌ´Ï¼ÅÆ¼ºêÀÎ À¯¿£ ÇÕµ¿ ¿¡ÀÌÁî ÇÁ·Î±×·¥(Joint United Nations Programme on HIV/AIDS)Àº 2021³â¿¡´Â ¾à 3,870¸¸ ¸íÀÌ HIV¿¡ °¨¿°µÉ °ÍÀ̸ç, ±× ¼ö´Â 2022³â¿¡´Â 3,900¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ̸ç, ±× Áß¿¡´Â °°Àº ÇØ ½Å±Ô °¨¿°ÀÚ 130¸¸ ¸íµµ Æ÷Ç﵃ °ÍÀ̶ó°í º¸°íÇß½À´Ï´Ù. °á°úÀûÀ¸·Î ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡´Â CCR5 ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

CCR5 ½ÃÀå ±â¾÷µéÀº °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ CCR5 ±æÇ×Á¦¿Í °°Àº ½Å¾à °³¹ß¿¡ ÁýÁßÇϰí ÀÖÀ¸¸ç, CCR5 ±æÇ×Á¦´Â ¸é¿ª¼¼Æ÷ÀÇ CCR5 ¼ö¿ëü¸¦ Â÷´ÜÇÏ¿© HIV¿Í °°Àº ƯÁ¤ º´¿øÃ¼°¡ ¼¼Æ÷¿¡ °áÇÕÇÏ¿© ħÀÔÇÏ´Â °ÍÀ» ¹æÁöÇÏ¿© °¨¿°À» ¾ïÁ¦ÇÏ°í ¸é¿ª ¹ÝÀÀ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¾àǰÀÔ´Ï´Ù. ¾àÁ¦ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 2¿ù ¹Ì±¹ »ý¸í°øÇÐ ±â¾÷ »çÀÌÅä´ÙÀÎ(CytoDyn Inc.)Àº ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ PRO140À¸·Îµµ ¾Ë·ÁÁø CCR5 ±æÇ×Á¦ÀÎ ·¼·Ð¸®¸¿(leronlimab)ÀÇ ÀÓ»ó º¸·ù¸¦ ÇØÁ¦Çß´Ù°í ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. À̹ø ½ÂÀÎÀ¸·Î »çÀÌÅä´ÙÀÎÀº ¸¸¼º ¿°Áõ¿¡ ´ëÇÑ ·¹·Ð¸®¸¿ÀÇ È¿°ú¸¦ Æò°¡Çϱâ À§ÇØ °èȹÇß´ø ÀÓ»ó½ÃÇèÀ» ÁøÇàÇÒ ¼ö ÀÖ°Ô µÆ½À´Ï´Ù. ·¹·Ð¸®¸¿Àº ¿©·¯ Áúº´À» Ç¥ÀûÀ¸·Î »ïÀ» ¼ö ÀÖ¾î HIV¿Í ¾ÏÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ °Ç°­ »óŸ¦ Ä¡·áÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª¹ÙÀÌ·¯½º, ±×¸®°í °æ±âȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

CC chemokine receptor type 5 (CCR5) is a protein found on the surface of white blood cells that plays a crucial role in the immune system by serving as a receptor for specific chemokines. These signaling molecules guide the movement of immune cells to areas of inflammation or infection. CCR5 is notably involved in the pathogenesis of diseases such as HIV, where it acts as a co-receptor, enabling the virus to enter and infect host cells, thus making it a target for therapeutic interventions.

The main types of CCR5-related compounds include BMS-813160, AG-1105, CCL-14, DS-001, and others. BMS-813160 is a small-molecule inhibitor developed by Bristol-Myers Squibb, designed to target specific receptors or pathways and is often investigated for its potential therapeutic effects in diseases such as cancer. Distribution channels for these compounds include hospitals, clinics, online pharmacies, and retail pharmacies. They are applied in various fields, including infectious diseases, gastrointestinal conditions, immunology, and oncology, and are used by different end-users such as research institutes, pharmaceutical companies, and healthcare facilities.

The CC chemokine receptor type 5 market research report is one of a series of new reports from The Business Research Company that provides CC chemokine receptor type 5 market statistics, including CC chemokine receptor type 5 industry global market size, regional shares, competitors with an CC chemokine receptor type 5 market share, detailed CC chemokine receptor type 5 market segments, market trends, and opportunities, and any further data you may need to thrive in the CC chemokine receptor type 5 industry. This CC chemokine receptor type 5 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The CC chemokine receptor type 5 market size has grown rapidly in recent years. It will grow from $1.4 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to government funding, R&D collaborations, public health campaigns, public-private partnerships, and the discovery of CCR5.

The CC chemokine receptor type 5 market size is expected to see rapid growth in the next few years. It will grow to $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to the prevalence of HIV or AIDS, healthcare infrastructure, economic incentives, increasing demand for healthcare, and economic growth. Major trends in the forecast period include expanding research on cancer treatment, development of combination therapies, development of pharmaceutical manufacturing, strategic collaborations and partnerships, and clinical trials expansion.

The growing prevalence of chronic diseases is expected to drive the expansion of the CC chemokine receptor type 5 (CCR5) market in the coming years. Chronic diseases are long-term medical conditions, such as heart disease, diabetes, and arthritis, which progress gradually and typically require ongoing management. The rise in chronic diseases can be attributed to aging populations and increasing rates of lifestyle-related risk factors, including poor diet, lack of physical activity, and obesity. CCR5 plays a key role in chronic diseases like human immunodeficiency virus (HIV), acting as a coreceptor that facilitates the virus's entry into immune cells and contributes to the disease's progression. For example, in October 2023, the Joint United Nations Programme on HIV/AIDS, a Switzerland-based global initiative focused on HIV prevention, reported that in 2021, approximately 38.7 million people were living with HIV, with the number rising to 39.0 million in 2022, including 1.3 million new infections that year. Consequently, the increasing prevalence of chronic diseases is fueling the growth of the CCR5 market.

Companies in the CCR5 market are focusing on developing new drugs, such as CCR5 antagonists, to maintain a competitive edge. CCR5 antagonists are medications that block the CCR5 receptor on immune cells, preventing certain pathogens such as HIV from binding and entering these cells, thereby inhibiting infection and influencing immune responses. For instance, in February 2024, CytoDyn Inc., a US-based biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on leronlimab, a CCR5 antagonist also known as PRO 140. This approval allows CytoDyn to proceed with its planned clinical trial to evaluate leronlimab's effects on chronic inflammation. Leronlimab shows potential for treating various health conditions, including HIV and cancer, due to its ability to target multiple diseases.

In October 2022, Amgen Inc., a US-based biopharmaceutical company, acquired ChemoCentryx for approximately $3.7 billion. This acquisition is aimed at enhancing Amgen's portfolio in inflammation and nephrology by incorporating ChemoCentryx's innovative therapeutics, such as TAVNEOS (avacopan), into its product lineup. ChemoCentryx is a US-based company specializing in CCR5-related medicines.

Major companies operating in the cc chemokine receptor type 5 market are Pfizer Inc., Sorrento Therapeutics, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Avexa Limited, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Gilead Sciences Inc., Vertex Pharmaceuticals, Ono Pharmaceutical Co Ltd, Abcam Limited, BioLegend Inc., R&D Systems Inc, American Gene Technologies International Inc, NSJ Bioreagents, Cytodyn Inc., Affinity Biosciences

North America was the largest region in the CC chemokine receptor type 5 market in 2024. The regions covered in the cc chemokine receptor type 5 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cc chemokine receptor type 5 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CC chemokine receptor type 5 market consists of sales of receptor antagonists, monoclonal antibodies, small molecule inhibitors, and gene editing therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CC Chemokine Receptor Type 5 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cc chemokine receptor type 5 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cc chemokine receptor type 5 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cc chemokine receptor type 5 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. CC Chemokine Receptor Type 5 Market Characteristics

3. CC Chemokine Receptor Type 5 Market Trends And Strategies

4. CC Chemokine Receptor Type 5 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global CC Chemokine Receptor Type 5 Growth Analysis And Strategic Analysis Framework

6. CC Chemokine Receptor Type 5 Market Segmentation

7. CC Chemokine Receptor Type 5 Market Regional And Country Analysis

8. Asia-Pacific CC Chemokine Receptor Type 5 Market

9. China CC Chemokine Receptor Type 5 Market

10. India CC Chemokine Receptor Type 5 Market

11. Japan CC Chemokine Receptor Type 5 Market

12. Australia CC Chemokine Receptor Type 5 Market

13. Indonesia CC Chemokine Receptor Type 5 Market

14. South Korea CC Chemokine Receptor Type 5 Market

15. Western Europe CC Chemokine Receptor Type 5 Market

16. UK CC Chemokine Receptor Type 5 Market

17. Germany CC Chemokine Receptor Type 5 Market

18. France CC Chemokine Receptor Type 5 Market

19. Italy CC Chemokine Receptor Type 5 Market

20. Spain CC Chemokine Receptor Type 5 Market

21. Eastern Europe CC Chemokine Receptor Type 5 Market

22. Russia CC Chemokine Receptor Type 5 Market

23. North America CC Chemokine Receptor Type 5 Market

24. USA CC Chemokine Receptor Type 5 Market

25. Canada CC Chemokine Receptor Type 5 Market

26. South America CC Chemokine Receptor Type 5 Market

27. Brazil CC Chemokine Receptor Type 5 Market

28. Middle East CC Chemokine Receptor Type 5 Market

29. Africa CC Chemokine Receptor Type 5 Market

30. CC Chemokine Receptor Type 5 Market Competitive Landscape And Company Profiles

31. CC Chemokine Receptor Type 5 Market Other Major And Innovative Companies

32. Global CC Chemokine Receptor Type 5 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The CC Chemokine Receptor Type 5 Market

34. Recent Developments In The CC Chemokine Receptor Type 5 Market

35. CC Chemokine Receptor Type 5 Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â